Oct 15 2009
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
- All Natural
- Non-Addictive
- Non-Narcotic
- Non-Opiate
- More Potent than Morphine
- Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
Childhood trauma linked to higher rates of somatic symptoms, study finds